V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20213191 | 20158235 | 1.64 | 89 | Palliative (P) | 2021-09-18 | 2021-10-10 | Carboplatin + Vinorelbine Oral | 02 | null | CAPECITABINE + NIVOLUMAB + OXALIPLATIN | 101484197 |
| 20214103 | 20158238 | 1.72 | 51.9 | Palliative (P) | 2016-12-03 | 2016-12-22 | Gemcitabine + RT pancreas | 02 | N | FOXTROT TRIAL | 100473129 |
| 20214385 | 20158240 | 1.66 | 70.2 | null | 2021-08-21 | 2021-08-22 | Cisplatin +FU +Trastuzumab - Maint | 02 | N | CARBO + FLUOROURACIL | 100402622 |
| 20214544 | 20158241 | 1.83 | 74.95 | Palliative (P) | 2016-12-30 | 2016-12-31 | null | 01 | N | SCOPE2 TRIAL | 101807236 |
| 20214585 | 20158242 | 1.53 | 77.8 | 03 | null | 2018-08-15 | MITOMYCIN | N | N | CETUXIMAB + IRINOTECAN | 100678103 |
| 20214764 | 20158243 | 1.75 | 87.1 | Neo-adjuvant (N) | 2016-03-23 | 2017-07-03 | Obinutuzumab | 02 | N | BORTEZOMIB | 101579208 |
| 20214788 | 20158244 | 1.54 | 68.9 | null | 2019-09-07 | 2019-09-09 | Hepatoblastoma HR Cisplatin | 02 | N | DOCETAXEL + NINTEDANIB | 101481309 |
| 20214936 | 20158246 | 1.52 | 84.8 | Palliative (P) | 2018-12-06 | 2018-12-26 | Bevacizumab + Capecitabine | 02 | N | CISPLATIN + CYTARABINE + ETOPOSIDE + RITUXIMAB | 101831960 |
| 20215121 | 20158248 | 1.54 | 87 | Curative (C) | 2017-12-25 | 2017-12-27 | Carboplatin + Docetaxel | 02 | N | CAV | 100546650 |
| 20215650 | 20158250 | 1.77 | 59.4 | Palliative (P) | 2020-04-29 | 2020-04-29 | ECF | 02 | N | OLAPARIB | 100892795 |
| 20215671 | 20158251 | 1.5 | 87.4 | null | 2017-10-15 | 2017-10-29 | FLUOROURACIL + Panitumumab | 02 | null | GEMCARBO | 101362840 |
| 20215844 | 20158252 | 1.52 | 60.4 | Palliative (P) | 2019-04-14 | 2019-04-24 | Cisplatin+Fluorouracil+Streptozoc | 02 | Y | BORTEZOMIB + DARATUMUMAB | 100420478 |
| 20215936 | 20158253 | 1.57 | 48.4 | null | 2019-02-08 | 2019-02-09 | FOXTROT TRIAL | 02 | N | RITUXIMAB | 101630201 |
| 20216203 | 20158254 | 1.55 | 46 | Curative (C) | 2020-06-29 | 2020-07-07 | Letrozole + Palbociclib | 02 | N | TOPOTECAN | 101603403 |
| 20216228 | 20158255 | 1.69 | 63.7 | Palliative (P) | null | 2017-10-27 | Bortezomib + CYCLOPHOSPHAMIDE | N | N | TRABECTEDIN | 100225055 |
| 20216277 | 20158256 | null | 65.8 | Curative (C) | 2018-12-24 | 2018-12-24 | INTERAACT trial | 02 | null | CAPECITABINE + LOMUSTINE | 101139226 |
| 20216410 | 20158257 | 1.6 | 85.8 | Curative (C) | 2016-06-04 | 2017-08-22 | CAV | 01 | N | FLUOROURACIL + OXALIPLATIN + TRASTUZUMAB | 101170759 |
| 20216432 | 20158258 | null | null | Neo-adjuvant (N) | 2021-09-22 | 2021-09-22 | Temozolomide + RT | 02 | N | PERTUZUMAB + TRASTUZUMAB | 101148368 |
| 20216504 | 20158259 | 1.8 | 121 | Disease modification (D) | 2018-09-23 | 2018-09-24 | Fluorouracil + Folinic + RT Bossett | 02 | N | CYCLOPHOSPHAMIDE + THALIDOMIDE | 100155579 |
| 20216542 | 20158260 | 1.58 | 0 | Palliative (P) | 2020-10-26 | 2020-10-26 | TCX | 02 | N | SCOPE2 TRIAL | 100867680 |
| 20216786 | 20158261 | 1.65 | 103 | Palliative (P) | 2018-01-20 | 2018-01-24 | CHOP - 14 days | 02 | null | CETUXIMAB + FLUOROURACIL | 101392092 |
| 20216833 | 20158262 | 1.71 | 90 | Disease modification (D) | 2022-03-19 | 2022-03-26 | ETOPOSIDE | 2 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101529017 |
| 20216940 | 20158264 | 1.63 | 75 | Palliative (P) | 2020-10-11 | 2020-10-11 | Irinotecan + Raltitrexed | 01 | N | CISPLATIN + FLUOROURACIL + RT | 100238300 |
| 20217055 | 20158265 | 1.61 | 14.5 | null | 2018-06-29 | 2018-08-05 | BUSULFAN | 01 | N | CISPLATIN + FU + TRASTUZUMAB | 101175464 |
| 20217411 | 20158266 | 1.6 | 7.8 | Palliative (P) | 2017-12-17 | 2017-12-17 | Trabectedin | 2 | N | CARBO + FLUOROURACIL | 101264157 |
| 20217473 | 20158267 | 1.61 | 61.6 | Palliative (P) | 2020-07-02 | 2020-08-20 | null | 02 | N | FOXTROT TRIAL | 101055865 |
| 20217550 | 20158268 | 1.56 | 62.45 | Curative (C) | 2019-09-07 | 2019-09-15 | Azacitidine | 02 | null | GDP | 101585541 |
| 20217723 | 20158269 | 1.69 | 53.3 | Neo-adjuvant (N) | 2020-06-16 | 2020-06-23 | GEMCARBO | 02 | N | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 100683398 |
| 20217738 | 20158270 | 1.51 | 78.1 | null | 2017-04-10 | 2017-04-24 | Binimetinib + Encorafenib | null | null | ECARBOX | 101110137 |
| 20218123 | 20158271 | 1.57 | 85.3 | Palliative (P) | 2020-04-24 | 2020-07-04 | ECF | 02 | N | GEFITINIB | 100937178 |
| 20218158 | 20158272 | 1.69 | 84 | Palliative (P) | 2020-08-12 | 2020-08-12 | Atezolizumab | N | N | LOMUSTINE | 100994352 |
| 20218161 | 20158273 | 1.73 | 55.05 | Palliative (P) | 2019-07-18 | 2019-07-19 | Gemcitabine + RT pancreas | N | N | SCOPE2 TRIAL | 100382991 |
| 20218548 | 20158275 | 1.65 | 65.6 | null | 2021-06-06 | 2021-06-10 | Cetuximab + Irinotecan (Cycle 1) | 99 | null | IRINOTECAN + FLUOROURACIL | 101591771 |
| 20218589 | 20158276 | 1.69 | 115.9 | Curative (C) | 2021-12-03 | 2022-04-23 | OXALIPLATIN + MDG + PANITUMUMAB | 02 | N | PEMETREXED | 100302031 |
| 20218603 | 20158277 | 1.65 | 68 | null | 2018-05-09 | 2018-05-09 | CAPE + OXALIPLATIN + TRASTUZUMAB | Y | N | BORTEZOMIB + THALIDOMIDE | 100081160 |
| 20219714 | 20158279 | 1.81 | 84.8 | Curative (C) | 2020-12-11 | 2020-12-11 | Hepatoblastoma VHR Block A Cisplatin/Dox | 02 | null | IBRUTINIB | 100321831 |
| 20219725 | 20158280 | 1.69 | 67 | null | 2020-12-01 | 2021-03-25 | CHOP R | 02 | null | ECARBOX | 100434847 |
| 20219987 | 20158281 | 1.52 | 20 | Curative (C) | 2018-05-26 | 2018-06-10 | Lomustine | 02 | null | CISPLATIN + DOCETAXEL + FLUOROURACIL | 100518188 |
| 20220087 | 20158282 | 1.61 | 72 | null | null | 2016-03-11 | null | N | null | DOCETAXEL + GEMCITABINE | 100619517 |
| 20220308 | 20158283 | 1.61 | 70 | Neo-adjuvant (N) | 2021-11-19 | 2021-11-19 | Arsenic trioxide + Tretinoin | N | N | ECF | 100517890 |
| 20220479 | 20158285 | 1.69 | 84.45 | Curative (C) | 2018-01-17 | 2018-01-17 | Cisplatin + Pemetrexed | 02 | N | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 100467656 |
| 20221836 | 20158287 | 1.86 | 84.8 | null | 2017-06-24 | 2017-07-17 | SCOPE 2 TRIAL | 02 | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101338877 |
| 20221863 | 20158288 | 1.47 | 54 | null | 2019-08-26 | 2019-09-23 | Vinorelbine (oral) | 02 | null | BEVACIZUMAB + FLUOROURACIL + IRINOTECAN | 101074111 |
| 20222527 | 20158289 | 1.57 | 69.3 | Curative (C) | 2020-02-29 | 2020-03-04 | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 2 | Y | FLUOROURACIL + PANITUMUMAB | 100265649 |
| 20224260 | 20158290 | 1.8 | null | Palliative (P) | 2020-06-24 | 2020-06-25 | null | Y | N | CETUXIMAB + IRINOTECAN | 101152026 |
| 20224380 | 20158291 | 0.9 | 65 | Curative (C) | 2017-01-13 | 2017-04-28 | DOXORUBICIN | N | null | IRINOTECAN + RALTITREXED | 100406326 |
| 20224442 | 20158292 | 1.56 | 87 | null | 2018-09-05 | 2018-09-07 | CAPE + OXALIPLATIN + TRASTUZUMAB | 02 | Y | CABAZITAXEL | 101312033 |
| 20224829 | 20158293 | 1.75 | 67.4 | null | null | 2019-02-13 | Niraparib | 02 | null | IVA | 100465200 |
| 20225073 | 20158294 | 1.69 | 65 | Curative (C) | 2018-11-28 | 2018-12-01 | CAPE + OXALIPLATIN + TRASTUZUMAB | 02 | N | BORTEZOMIB + DARATUMUMAB | 100693247 |
| 20013659 | 20158297 | 0.92 | 80.95 | Curative (C) | 2020-02-04 | 2020-02-18 | ACTICCA-1 Trial | N | null | IBRUTINIB | 100521861 |